Fulcrum Therapeutics (FULC) Cash from Financing Activities (2018 - 2026)
Fulcrum Therapeutics (FULC) reported Cash from Financing Activities of -$312000.0 for Q1 2026, down 100.19% quarter-over-quarter from $168.3 million in Q4 2025.
Fulcrum Therapeutics (FULC) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 9 years of Cash from Financing Activities data on file, last reported at -$312000.0 in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$312000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $168.4 million (up 15274.89% YoY), and the FY2025 annual result was $168.7 million, up 6042.28% from the prior year.
- Cash from Financing Activities eased to -$312000.0 in Q1 2026 per FULC's latest filing, from $168.3 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $168.3 million in Q4 2025 and troughed at -$312000.0 in Q1 2026.
- A 5-year average of $24.9 million and a median of $348000.0 in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities tumbled 99.27% in 2022, then soared 202673.49% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $218000.0 in 2022, then jumped by 31.65% to $287000.0 in 2023, then sank by 71.08% to $83000.0 in 2024, then soared by 202673.49% to $168.3 million in 2025, then slumped by 100.19% to -$312000.0 in 2026.
- Business Quant data shows FULC's Cash from Financing Activities at -$312000.0 in Q1 2026, $168.3 million in Q4 2025, and $64000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 85,464.43 |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | -312,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -312,000.00 |
| Mar 31, 2026 | -312,000.00 |
| Dec 31, 2025 | 168.30 Mn |
| Dec 31, 2025 | 168.30 Mn |
| Sep 30, 2025 | 64,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Jun 30, 2025 | 301,000.00 |
| Jun 30, 2025 | 301,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Sep 30, 2024 | 635,000.00 |
| Sep 30, 2024 | 635,000.00 |
| Jun 30, 2024 | 377,000.00 |
| Jun 30, 2024 | 377,000.00 |
| Mar 31, 2024 | 1.65 Mn |
| Mar 31, 2024 | 1.65 Mn |
| Dec 31, 2023 | 287,000.00 |
| Dec 31, 2023 | 287,000.00 |
| Jun 30, 2023 | 142,000.00 |
| Jun 30, 2023 | 142,000.00 |